Use of cerebrospinal fluid biomarkers in diagnosis of dementia across Europe
- 18 December 2009
- journal article
- Published by Wiley in European Journal of Neurology
- Vol. 17 (1), 90-96
- https://doi.org/10.1111/j.1468-1331.2009.02753.x
Abstract
Cerebrospinal fluid (CSF) biomarkers have been reported to be useful in dementia diagnosis. Not much is known about their use in clinical practice in Europe.We analyzed data from a survey on the use of CSF biomarkers in the diagnosis of dementia across Europe using a questionnaire which was filled out by representatives of the 25 member countries of the European Federation of Neurological Societies (EFNS).Cerebrospinal fluid beta-amyloid, total tau, and phosphorylated tau proteins are frequently evaluated in the majority of the countries (in 18 out of 23 countries). No major technical or ethical issues were found that would hamper the procedure's ability to become routine in early and differential diagnostics of Alzheimer's disease. Cut-off values for beta-amyloid (median 500, range 300-849 pg/ml), total tau (367; 195-450 pg/ml) and phosphorylated tau (60; 40-85 pg/ml) varied considerably amongst countries and even within every country.Cerebrospinal fluid analysis of beta-amyloid, tau, and phosphorylated tau is frequently used in Europe. However, the use of various cut off values seriously hampers comparability and yields a potential threat to an interpretation and balanced use in clinical practice. We recommend that each laboratory establishes normative data and that multi-centered studies should be organized to explore the reasons for any differences.This publication has 15 references indexed in Scilit:
- CSF and MRI markers independently contribute to the diagnosis of Alzheimer's diseaseNeurobiology of Aging, 2008
- Variability in longitudinal cerebrospinal fluid tau and phosphorylated tau measurementscclm, 2008
- Diagnostic Value of CSF Biomarker Profile in Frontotemporal Lobar DegenerationAlzheimer Disease & Associated Disorders, 2008
- Cerebrospinal Fluid tau/β-Amyloid42 Ratio as a Prediction of Cognitive Decline in Nondemented Older AdultsArchives of Neurology, 2007
- Fluctuations of CSF amyloid-β levelsNeurology, 2007
- Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up studyThe Lancet Neurology, 2006
- Analytical performance and clinical utility of the INNOTEST® PHOSPHO-TAU(181P) assay for discrimination between Alzheimer's disease and dementia with Lewy bodiescclm, 2006
- CSF Aβ42 and tau or phosphorylated tau and prediction of progressive mild cognitive impairmentNeurology, 2005
- Effects of Processing and Storage Conditions on Amyloid β (1–42) and Tau Concentrations in Cerebrospinal Fluid: Implications for Use in Clinical PracticeClinical Chemistry, 2005
- Clinical diagnosis of Alzheimer's diseaseNeurology, 1984